Abstract
BackgroundFor decades, conventionally fractionated whole breast irradiation (CF-WBI) was used after breast conserving surgery (BCS). Pivotal phase 3 trials on hypofractionated-WBI (HF-WBI) showed its non-inferiority as compared to CF-WBI. However, younger patients (<60 years) are not currently worldwide treated with HF-WBI. The aim of this multi-center comparative study is to confirm the safety of HF-WBI in a real-life series of younger patients. MethodsBetween 2010 and 2016, a total of 786 patients aged less than 60 years old with early stage breast cancer were treated with postoperative WBI after BCS in three breast cancer centers: 340 underwent HF-WBI while 446 were treated with CF-WBI. Acute toxicity was evaluated at the end of WBI. Late toxicity was evaluated at 6, 12, 24, and 36 months. ResultsAt univariate logistic analysis, hypofractionation showed a significant protective effect in terms of acute edema (p=0.0001), acute wet desquamation (p=0.009), chronic edema (p=0.0001), chronic erythema/pigmentation (p=0.0001), and breast fibrosis (p=0.0002). At multivariate logistic analysis, hypofractionation was independent significant factor for acute edema (OR 0.09, 95% CI 0.02 to 0.48; p=0.005), acute wet desquamation (OR 0.07, 95% CI 0.009 to 0.59; p=0.014), and chronic edema (OR 0.18, 95% CI 0.04 to 0.75; p=0.018). Significant association between individual characteristics and toxicity (grade 2 or more) are summarized in Table.Table215PTableToxicityNProtective factorp-valueOR (95%CI)Risk factorp-valueOR (95%CI)Acute edema43Hypofractionation Dmax/Prescribed dose° <107%0.0001 0.0010.09 (0.03-0.30) 0.16 (0.06-0.46)Chemotherapy0.0022.63 (1.42-4.90)Chronic edema50Hypofractionation Dmax/Prescribed dose° <107%0.0001 0.0030.20 (0.09-0.44) 0.31 (0.14-0.66)EIC presence Boost dose >10Gy Breast size >492cc0.0001 0.032 0.0033.0 (1.66-5.46) 9.02 (1.21-67.45) 2.67 (1.41-5.05)Acute erythema/ pigmentation163HER2 positive status Trastuzumab0.002 0.0220.30 (0.14-0.63) 0.39 (0.18-0.87)Smoking habits Boost dose >10Gy Breast size >492cc0.001 0.038 0.0022.14 (1.37-3.32) 2.60 (1.06-6.41) 1.78 (1.24-2.54)Chronic erythema/ pigmentation110Hypofractionation Dmax/Prescribed dose° <107%0.0001 0.0010.40 (0.25-0.63) 0.45 (0.28-0.73)EIC presence Positive FSM Boost dose >10Gy Breast size >492cc0.0001 0.002 0.007 0.0342.39 (1.54-3.71) 3.47 (1.56-7.71) 15.43 (2.08-114.3) 1.58 (1.04-2.41)Acute wet desquamation20Hypofractionation Dmax/Prescribed dose° <107%0.009 0.0470.14 (0.03-0.61) 0.29 (0.08-0.99)---Breast fibrosis117Hypofractionation Tumor grade Ki67 index Dmax/Prescribed dose° <107%0.0002 0.022 0.023 0.0170.44 (0.29-0.68) 0.53 (0.31-0.92) 0.60 (0.38-0.93) 0.58 (0.37-0.91)EIC presence Boost dose >10Gy Breast size >492cc0.0001 0.022 0.00013.03 (1.99-4.62) 6.76 (2.04-22.45) 2.84 (1.83-4.41) ConclusionsHF-WBI showed significantly improved toxicity outcomes in terms of both acute skin edema and wet desquamation, and chronic skin edema. HF-WBI after BCS should replace CF-WBI independently of age. Legal entity responsible for the studyThe authors. FundingHas not received any funding. DisclosureAll authors have declared no conflicts of interest.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call